With A Reputation As The World’s Largest Company Involved In The Production And Commercialization Of Cannabis-based Therapeutics, Gw Pharmaceuticals /quotes/zigman/15446670/composite Gwph -2.04% Has Operations In Europe, Canada, The United States And Asia.

Acquisitions help public companies diversify their portfolios and revenue streams while providing private companies access to more financing. Public companies such as SinglePoint, Inc. /quotes/zigman/18904875/delayed SING -4.92% ( SING Profile ) , Vinergy Resources Ltd. /quotes/zigman/84612962/delayed VNNYF -4.17% http://www.michiganmedicalmarijuana.biz and ChineseInvestors .com , Inc. /quotes/zigman/72554234/delayed CIIX +3.87% have already initiated or completed such acquisitions, encouraged by the significant growth potential that cannabis-based product manufacturing businesses bring to the table. This impressive potential is perfectly exemplified by GW Pharmaceuticals plc /quotes/zigman/15446670/composite GWPH -2.04% , a biopharma company focused on developing cannabinoid prescription medicines. With a reputation as the world’s largest company involved in the production and commercialization of cannabis-based therapeutics, GW Pharmaceuticals /quotes/zigman/15446670/composite GWPH -2.04% has operations in Europe, Canada, the United States and Asia. Based on its proprietary cannabinoid product platform, GW Pharma has developed therapies for the treatment of various conditions, including multiple sclerosis-related spasticity and neuropathic pain. Its product pipeline is also targeting tuberculosis sclerosis complex, infantile spasms, adult epilepsy, schizophrenia and more.

To read more visit http://www.marketwatch.com/(S(rnrsydaynixa5x55oiibxm45))/story/marijuana-industry-acquisitions-on-the-rise-as-companies-to-diversify-portfolios-increase-revenue-streams-2017-02-15

Comments are closed.